Robert Barnes
Internal Medicine · Senatobia, MSNPI 1720577380
Payments from drug & device makers
Across 121 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$517
- Novo Nordisk$378
- AbbVie$309
- Lilly USA, LLC$227
- GSK$157
- Pfizer$125
- plus $817 from 19 others
What the payments were for
- Food & beverage$2,523100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $517 |
| Novo Nordisk | 21 | $378 |
| AbbVie | 17 | $309 |
| Lilly USA, LLC | 12 | $227 |
| GSK | 9 | $157 |
| Pfizer | 7 | $125 |
| Esperion Therapeutics, Inc. | 2 | $109 |
| Boehringer Ingelheim | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $95 |
| Biogen | 1 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $51 |
| Bayer | 2 | $41 |
| Eisai Inc. | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Mylan Specialty L.p. | 1 | $31 |
| Shield Therapeutics Inc | 2 | $31 |
| Amgen | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$2,530 in reported general payments places this provider in the 75th percentile of 846 internal medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 362 | $397,080 |
| JardianceEmpagliflozin | 158 | $222,747 |
| FarxigaDapagliflozin Propanediol | 180 | $181,822 |
| OzempicSemaglutide | 123 | $119,509 |
| TrulicityDulaglutide | 78 | $77,975 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $72,639 |
| EliquisApixaban | 73 | $63,645 |
| RybelsusSemaglutide | 50 | $52,950 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $41,704 |
| Xigduo XrDapaglifloz Propaned/Metformin | 40 | $41,063 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $38,392 |
| XareltoRivaroxaban | 29 | $36,082 |
| LinzessLinaclotide | 28 | $34,271 |
| TradjentaLinagliptin | 37 | $33,714 |
| EntrestoSacubitril/Valsartan | 38 | $28,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $227 | $475,054440 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Spiriva Respimat | $102 | $347,110264 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $517 | $234,991249 claims |
| Novo NordiskOzempic, Rybelsus | $378 | $172,459173 claims |
| PfizerEliquis | $125 | $63,64573 claims |
| GSKTrelegy Ellipta | $157 | $41,70453 claims |
| AbbVieLinzess | $309 | $34,27128 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $14,50416 claims |
| Eisai Inc.Dayvigo | $40 | $11,37740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Senatobia
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.